Menu Search
Equities

Grand Pharmaceutical Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MX6A:FRA

Grand Pharmaceutical Group Ltd

Actions
  • Price (EUR)0.785
  • Today's Change-0.02 / -2.48%
  • Shares traded480.00
  • 1 Year change+49.52%
  • Beta0.8606
Data delayed at least 15 minutes, as of Feb 12 2026 08:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Grand Pharmaceutical Group Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the manufacture and sale of pharmaceutical preparations and medical devices. The Company is also engaged in the manufacture and sale of biotechnology products, health products, specialised pharmaceutical raw materials and other products. The Company's main products include nuclear medicine anti-tumor diagnosis and treatment and cardiovascular and cerebrovascular interventional diagnosis and treatment technology products.

  • Revenue in HKD (TTM)11.70bn
  • Net income in HKD2.08bn
  • Incorporated1995
  • Employees12.44k
  • Location
    Grand Pharmaceutical Group LtdUnits 3302The Center, 99 Queen's Road Central Hong KongHKG
  • Phone+852 28663718
  • Fax+852 28662521
  • Websitehttps://www.grandpharma.cn/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		512:HKG since
announced		Transaction
value
Nanjing Kainite Medical Technology Co LtdAnnounced21 Feb 202521 Feb 2025Announced59.49%15.08m
Data delayed at least 15 minutes, as of Feb 12 2026 08:08 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.